Mohammad Tabrizi

Mo (Mohammad) Tabrizi, Ph.D., joined Soteria in 2021, bringing over 25 years of experience in basic research, integrative pharmacology, translational sciences, and the development of protein-based biologics. Prior to joining Soteria, Dr. Tabrizi served in positions with increasing responsibilities at companies such as Ascendis Pharma, Merck Research Laboratories, AstraZeneca/Medimmune, and Abgenix. His product development experience spans many therapeutic areas including oncology, immune-oncology, and inflammatory diseases. He has been an author or co-inventor on more than 50 original papers, reviews, book chapters, published books, and patents. Dr. Tabrizi has been an invited speaker to numerous national and international conferences. Dr. Tabrizi received his bachelor’s degree in Pharmacy from the University of Houston (Summa Cum Laude) and his Ph.D. in Pharmaceutical Sciences from the University at Buffalo, State University of New York. He completed postdoctoral training in Pharmacology, with a focus on therapeutics, at the University of New York at Buffalo.